Tao Synergies Inc (TAOX)

$5.70 -0.33 (-5.47%)
Market Cap 48.94M
Revenue (ttm) 300,000.00
Net Income (ttm) -28.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,580.00%
Debt to Equity Ratio 0.00
Volume 119,600
Avg Vol 202,578
Day's Range N/A - N/A
Shares Out 7.47M
Stochastic %K 59%
Beta 1.49
Analysts Strong Buy
Price Target N/A

Company Profile

TAO Synergies Inc. owns and operates an AI token. The company executes a cryptocurrency treasury strategy centered on the acquisition and staking of the TAO token, the native utility token of the Bittensor network. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.

Industry: Software - Infrastructure
Sector: Technology
Phone: 973 242 0005
Address:
1185 Avenue of the Americas, 3rd Floor, New York, United States
EndGame1
EndGame1 May. 12 at 9:33 PM
$DGXX $8/share and still 100% margin requirement at Schwab. Also, my two other $4+ stocks $TAOX and $FABC They do give it to
0 · Reply
EndGame1
EndGame1 May. 12 at 6:56 PM
$TAOX Fools for selling...I say. "Bittensor (TAO) Upgrade Revises Subnet Emissions Criteria: Bittensor (TAO) implements a May 13 protocol upgrade, revising subnet emissions criteria. This prevents subsidizing loss-making subnets, shifting the network from net TAO outflow to inflow and reducing supply."
0 · Reply
SnoopyPotter
SnoopyPotter May. 12 at 12:33 PM
$TAOX $TAOX - James Altucher just dropped a strong bullish take:"At $TAOX, the largest public holder of $TAO.X, we are super bullish. $TAO.X is the largest decentralized AI platform — basically an ETF of 128 state-of-the-art AI subnets. One subnet fails? Zero impact on the whole. With a ~$3B market cap vs OpenAI at $1.5T, the upside is massive. The team (led by @const ) has real integrity, and the project keeps evolving through governance and tech upgrades.This isn’t just crypto — it’s a working, under-the-radar AI network that’s succeeding. $TAOX is the easiest public vehicle to own it.Patience required, but Altucher says he’s a seller at $100. Long $TAOX "
1 · Reply
EndGame1
EndGame1 May. 11 at 7:49 PM
$TAOX Maybe tomorrow we break $7. $TAO.X up to $326.
0 · Reply
EndGame1
EndGame1 May. 11 at 5:48 PM
$TAOX Price has tested $6.90 several times today. Maybe next time a go. Bittensor TAO Price #35 $322.04 +14.1% (7d)
0 · Reply
EndGame1
EndGame1 May. 11 at 3:16 PM
$TAOX Volume is coming back. 10K shares for sale at $6.76. $340 range was where Sam sent us lower. It's been a while since Bittensor was rank 35. Bittensor TAO Price #35 $324.63 +107.0% (3m)
0 · Reply
nofunanymore
nofunanymore May. 11 at 3:15 PM
$TAOX $DGXX $SOFI $BLNE almost as much fun going from 32.73 to 16
1 · Reply
EndGame1
EndGame1 May. 11 at 2:56 PM
$TAOX What a fun day. My $DGXX is up +250%. Almost as good as when my OUST went from $3.80 to $40. And my $SOFI went from $8 to $30. And few even know of DGXX yet. They will after the Cerebras IPO Wednesday. TAOX, FABC, DVLT, SOFI and $BLNE will be next, with multibaggers.
0 · Reply
EndGame1
EndGame1 May. 11 at 1:52 PM
$TAOX Maybe $7 today? "Bittensor Ecosystem Expands Amidst Supply Tightening and Whale Accumulation: Bittensor (TAO) has seen increased interest driven by expanding ecosystem tools like Taostats, and significant supply tightening due to high staking rates and exchange outflows. Whale accumulation in subnet SN62 also contributes to positive market sentiment." "Bittensor Ecosystem Expands with Analytics and Compute Onboarding Tools: Bittensor's ecosystem expands with Taostats for analytics and new onboarding tools like Targon Supply Portal and TaonSquare. These tools aim to reduce information friction and enhance large-scale compute onboarding."
0 · Reply
EndGame1
EndGame1 May. 11 at 1:29 PM
$TAOX This should go over $7 this week. Bittensor TAO Price #35 $320.59 +1.2% (24h)
0 · Reply
Latest News on TAOX
Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

Nov 18, 2025, 5:15 PM EST - 6 months ago

Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

BEX CSEX NNEX SNPX

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Nov 18, 2025, 9:15 AM EST - 6 months ago

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

Nov 13, 2025, 6:46 AM EST - 6 months ago

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

BEX CSEX NNEX SNPX

TAO Synergies files to sell 22.3M shares of common stock for holders

2025-11-12T21:22:16.000Z - 6 months ago

TAO Synergies files to sell 22.3M shares of common stock for holders

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

Nov 11, 2025, 11:26 AM EST - 6 months ago

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

BEX CSEX NNEX SNPX

TAO Synergies announces initial $750K investment in Bittensor Subnet Funds

2025-11-04T14:20:39.000Z - 6 months ago

TAO Synergies announces initial $750K investment in Bittensor Subnet Funds

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

Nov 4, 2025, 9:15 AM EST - 6 months ago

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

TAO Synergies reports total TAO increased to 54,058 tokens

2025-10-20T13:20:22.000Z - 7 months ago

TAO Synergies reports total TAO increased to 54,058 tokens

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

Oct 20, 2025, 9:15 AM EDT - 7 months ago

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

TAO Synergies announces $11M private placement

2025-10-13T21:15:14.000Z - 7 months ago

TAO Synergies announces $11M private placement

TAO Synergies Announces $11 Million Private Placement

Oct 13, 2025, 5:09 PM EDT - 7 months ago

TAO Synergies Announces $11 Million Private Placement

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

Sep 22, 2025, 9:15 AM EDT - 8 months ago

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

Sep 8, 2025, 9:15 AM EDT - 8 months ago

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

Aug 26, 2025, 9:15 AM EDT - 9 months ago

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

TAO Synergies files $100M mixed securities shelf

2025-08-14T20:55:13.000Z - 9 months ago

TAO Synergies files $100M mixed securities shelf

TAO Synergies acquires $10M of Bittensor

2025-07-17T13:21:08.000Z - 10 months ago

TAO Synergies acquires $10M of Bittensor

TAO Synergies files to sell 5.04M shares of common stock for holders

2025-07-11T21:05:08.000Z - 10 months ago

TAO Synergies files to sell 5.04M shares of common stock for holders

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Jul 1, 2025, 9:15 AM EDT - 11 months ago

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Jun 26, 2025, 9:15 AM EDT - 11 months ago

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Jun 24, 2025, 9:15 AM EDT - 11 months ago

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Jun 9, 2025, 9:00 AM EDT - 1 year ago

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Dec 20, 2024, 9:15 AM EST - 1 year ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix Announces $5.0 Million Financing

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jul 18, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Jun 26, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 24, 2024, 9:15 AM EDT - 2 years ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D.

Dec 19, 2023, 9:00 AM EST - 2 years ago

Synaptogenix President Daniel L. Alkon, M.D.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Dec 6, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 26, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Sep 7, 2023, 9:00 AM EDT - 2 years ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 19, 2023, 9:00 AM EDT - 3 years ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Jul 13, 2023, 9:00 AM EDT - 3 years ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Mar 7, 2023, 9:00 AM EST - 3 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Dec 16, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Nov 18, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Oct 19, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Sep 28, 2022, 11:50 AM EDT - 3 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Aug 12, 2022, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 26, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Synaptogenix Announces Corporate Update Conference Call

Jul 21, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Announces Corporate Update Conference Call

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Jul 20, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Synaptogenix to Present at the Cell Symposium

May 17, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at the Cell Symposium

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 19, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Apr 5, 2022, 9:15 AM EDT - 4 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 29, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 22, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Mar 15, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 23, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Feb 1, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 10, 2021, 9:00 AM EDT - 5 years ago

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Aug 5, 2021, 10:00 AM EDT - 5 years ago

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Jul 26, 2021, 9:15 AM EDT - 5 years ago

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Jul 21, 2021, 9:00 AM EDT - 5 years ago

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Jul 14, 2021, 9:00 AM EDT - 5 years ago

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

EndGame1
EndGame1 May. 12 at 9:33 PM
$DGXX $8/share and still 100% margin requirement at Schwab. Also, my two other $4+ stocks $TAOX and $FABC They do give it to
0 · Reply
EndGame1
EndGame1 May. 12 at 6:56 PM
$TAOX Fools for selling...I say. "Bittensor (TAO) Upgrade Revises Subnet Emissions Criteria: Bittensor (TAO) implements a May 13 protocol upgrade, revising subnet emissions criteria. This prevents subsidizing loss-making subnets, shifting the network from net TAO outflow to inflow and reducing supply."
0 · Reply
SnoopyPotter
SnoopyPotter May. 12 at 12:33 PM
$TAOX $TAOX - James Altucher just dropped a strong bullish take:"At $TAOX, the largest public holder of $TAO.X, we are super bullish. $TAO.X is the largest decentralized AI platform — basically an ETF of 128 state-of-the-art AI subnets. One subnet fails? Zero impact on the whole. With a ~$3B market cap vs OpenAI at $1.5T, the upside is massive. The team (led by @const ) has real integrity, and the project keeps evolving through governance and tech upgrades.This isn’t just crypto — it’s a working, under-the-radar AI network that’s succeeding. $TAOX is the easiest public vehicle to own it.Patience required, but Altucher says he’s a seller at $100. Long $TAOX "
1 · Reply
EndGame1
EndGame1 May. 11 at 7:49 PM
$TAOX Maybe tomorrow we break $7. $TAO.X up to $326.
0 · Reply
EndGame1
EndGame1 May. 11 at 5:48 PM
$TAOX Price has tested $6.90 several times today. Maybe next time a go. Bittensor TAO Price #35 $322.04 +14.1% (7d)
0 · Reply
EndGame1
EndGame1 May. 11 at 3:16 PM
$TAOX Volume is coming back. 10K shares for sale at $6.76. $340 range was where Sam sent us lower. It's been a while since Bittensor was rank 35. Bittensor TAO Price #35 $324.63 +107.0% (3m)
0 · Reply
nofunanymore
nofunanymore May. 11 at 3:15 PM
$TAOX $DGXX $SOFI $BLNE almost as much fun going from 32.73 to 16
1 · Reply
EndGame1
EndGame1 May. 11 at 2:56 PM
$TAOX What a fun day. My $DGXX is up +250%. Almost as good as when my OUST went from $3.80 to $40. And my $SOFI went from $8 to $30. And few even know of DGXX yet. They will after the Cerebras IPO Wednesday. TAOX, FABC, DVLT, SOFI and $BLNE will be next, with multibaggers.
0 · Reply
EndGame1
EndGame1 May. 11 at 1:52 PM
$TAOX Maybe $7 today? "Bittensor Ecosystem Expands Amidst Supply Tightening and Whale Accumulation: Bittensor (TAO) has seen increased interest driven by expanding ecosystem tools like Taostats, and significant supply tightening due to high staking rates and exchange outflows. Whale accumulation in subnet SN62 also contributes to positive market sentiment." "Bittensor Ecosystem Expands with Analytics and Compute Onboarding Tools: Bittensor's ecosystem expands with Taostats for analytics and new onboarding tools like Targon Supply Portal and TaonSquare. These tools aim to reduce information friction and enhance large-scale compute onboarding."
0 · Reply
EndGame1
EndGame1 May. 11 at 1:29 PM
$TAOX This should go over $7 this week. Bittensor TAO Price #35 $320.59 +1.2% (24h)
0 · Reply
TaoistTrader
TaoistTrader May. 9 at 2:11 PM
$TAOX I see reverse h&s on the chart. Looking really good $TAO.X
0 · Reply
EndGame1
EndGame1 May. 8 at 2:23 PM
$TAOX Bittensor TAO Price #36 $311.65 +1.1% (24h) "Bittensor (TAO) Sees Adoption Grow with Minos and CoinGecko Feature: Minos SN107 is validating genomes on bittensor:native (Phase 1), while CoinGecko features TAO subnets. This indicates growing real-world usage and visibility." "Bittensor (TAO) Noted as Beneficiary of Decentralized AI Compute Rotation: Bittensor (TAO) is identified as a beneficiary of a post-Consensus 2026 thematic rotation into decentralized AI compute. Institutional validation from JPMorgan, Mastercard, and Nasdaq, alongside increased capital, highlights TAO's potential for demand growth."
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam May. 7 at 7:28 PM
$TAOX Not selling. I want way more than 25-30%
0 · Reply
EndGame1
EndGame1 May. 7 at 7:00 PM
$TAOX Maybe $TAO.X $320 overnight. "Tokenomist Launches Dashboard for Bittensor Subnet Tokens: Tokenomist introduced a live dashboard for Bittensor subnet tokens, increasing visibility and analytics access for individual subnet assets within the ecosystem."
0 · Reply
EndGame1
EndGame1 May. 7 at 2:02 PM
$TAOX Liking the price action. Slow move up is better. Bittensor TAO Price Up to #35 $309.71 +1.5% "Bittensor Subnets Tokenized with dTAO, Each Receiving Own Token: Bittensor's subnets are tokenized with dTAO, granting each subnet its own token. This introduces a material tokenomics shift, enabling direct capital flow and increasing on-chain activity." "Bittensor (TAO) Implements Conviction Locks, Mainnet Deployment Set for May 13: Bittensor (TAO) has implemented Conviction locks (spec v403). This update auto-locks subnet owner emissions and 18% of Alpha on-chain. Unlocks reduce conviction over 70-80 days. Mainnet deployment is May 13."
0 · Reply
EndGame1
EndGame1 May. 7 at 1:17 PM
$TAOX Another nice day. That said it may come back and close the $6.60 daily gap up.
0 · Reply
MasterOfMyDomains
MasterOfMyDomains May. 7 at 10:55 AM
$TAOX What's cooking?
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam May. 7 at 9:29 AM
$TAOX Amazing!
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam May. 7 at 8:34 AM
$TAOX $6.99 pre-market??
0 · Reply
Jimmybelanger3
Jimmybelanger3 May. 7 at 2:46 AM
$TAOX how high can we go?
0 · Reply
SnoopyPotter
SnoopyPotter May. 7 at 2:03 AM
$TAOX $TAOX A note to all $TAO.X holders: You’re absolute legends for sticking it out through the toughest times. Your patience is about to pay off. The markets are heating up again — crypto and AI are here for the long haul. HIGHER.
0 · Reply
Jimmybelanger3
Jimmybelanger3 May. 6 at 11:21 PM
$TAOX
0 · Reply